6 results about "Intestinal mucous membrane" patented technology

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The application belongs to the field of biomedical materials, targeted drug delivery technology and ulcerative colitis treatment, and discloses a curcumin-loaded claspable composite microneedle and a preparation method thereof. The composite microneedle comprises a curcumin-loaded gelatin hemisphere base and a curcumin-loaded chitosan-polyvinyl alcohol microneedle, and the microneedle is located on the circular end face of the hemisphere base. The curcumin in the base and the microneedle is loaded in the form of curcumin-cyclodextrin inclusion compound. The claspable composite microneedle is formed by designing a hemisphere base + microneedle array, and the hemisphere base + microneedle part of the composite microneedle is loaded with curcumin, which can relieve and treat intestinal wall and intestinal mucosa damage caused by ulcerative colitis, indirectly inhibit intestinal flora disorder and abnormal activation of the inflammatory immune system, so as to solve the technical problem of low cure rate of ulcerative colitis, and provide a more safe and efficient treatment strategy for targeted intestinal diseases.

The application discloses a use of a ganoderma lucidum spore and grifola frondosa composition in preparation of a preparation for assisting in relieving colorectal cancer. The composition comprises ganoderma lucidum spore oil, squalene, grifola frondosa extract, selenium-rich yeast and the like, and is prepared into soft capsules by using a cold preparation method. A mouse model experiment induced by AOM / DSS proves that the soft capsules can significantly relieve weight loss of mice, reduce a disease activity index, improve colon shortening, inhibit expression of inflammatory factors TNF-alpha and IL-6 in serum and colon tissues, reduce intestinal inflammatory reactions, repair colon crypt structure and intestinal mucosal damage, down-regulate expression of a proliferation marker Ki 67, up-regulate expression of an apoptosis marker Caspase-3, induce tumor cell apoptosis, regulate intestinal flora structure, restore relative abundance of Bacteroidetes and Firmicutes, and reverse abnormal increase of Verrucomicrobia. The application can act on the whole process from intestinal polyps, precancerous lesions to colorectal cancer development, is safe and stable, can be taken for a long time, and has high application value.

The application discloses a biological membrane material, a preparation method thereof and an artificial heart valve. The preparation method of the biological membrane material comprises the following steps: S100, providing a biological membrane, wherein the biological membrane is derived from pericardium, blood vessels, intestinal mucosa or ligament; S200, applying a pulling force to the biological membrane, wherein at least one to-be-processed area of the biological membrane has two opposite side edges as force receiving parts, the pulling force is applied to the two side edges in opposite directions, and each side edge is provided with integral fixation or multiple fixation positions arranged along the extension direction of the side edge; and S300, performing cross-linking treatment on the biological membrane under the pulling force to obtain the biological membrane material. The biological membrane is kept in a stretched and tensioned state by applying the pulling force in the same direction as the fiber direction of the biological membrane, and the thickening effect of the biological membrane during the cross-linking treatment can be effectively inhibited.

The invention discloses application of a gingko armillaria mellea oral solution in preparation of a medicine for preventing and treating inflammatory bowel diseases. Through a prevention and treatment test of the ginkgo armillaria mellea oral solution on mouse ulcerative colitis, a C57BL / 6 mouse DSS induction method is adopted to construct a model, and the effect of 390mg / kg and 780mg / kg of the ginkgo armillaria mellea oral solution on resisting mouse inflammatory bowel diseases is evaluated. The result shows that the gingko armillaria mellea oral solution can obviously improve the mouse hematochezia condition; the colon length is increased, the colon weight / length ratio is reduced, and colonic mucosa hyperemia is reduced; the weight is increased. Therefore, the gingko armillaria mellea oral solution has the characteristics of high efficiency and low toxicity for preventing and / or treating inflammatory bowel diseases.

The application discloses a Lacticaseibacillus paracasei W1 and application of the Lacticaseibacillus paracasei W1 in inhibition of Clostridioides difficile infection, relates to the technical field of probiotic application, and has the technical points that the preservation number of the Lacticaseibacillus paracasei W1 is CCTCC No:M 2024619. The Lacticaseibacillus paracasei W1 has the ability of resisting low pH and high concentration of bile salts in the gastrointestinal tract, and sterile fermentation supernatant of the Lacticaseibacillus paracasei W1 can inhibit growth and biofilm formation of Clostridioides difficile. Animal experiments show that the Lacticaseibacillus paracasei W1 can inhibit colonization of Clostridioides difficile in vivo, improve colon mucosal injury, relieve colon shortening, and reduce inflammation caused by Clostridioides difficile infection. The strain has a wide application prospect in the application in preparation of a medicine for inhibiting Clostridioides difficile infection.